![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
April 24, 2025
Summaries of recently published ECOG-ACRIN research results
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
August 14, 2024
A Scientific Member of ECOG-ACRIN since 2012
April 9, 2024
This phase 2/3 trial is comparing the safety and efficacy of treatment with nivolumab, ipilimumab, and sargramostim to treatment with nivolumab and ipilimumab alone
February 9, 2024
The co-chairs commemorate the late Dr. Edith Mitchell, welcome the new NCI Director, and reflect on the DREAMseq melanoma trial results
April 19, 2023
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
November 16, 2021
Practice-changing trial results in melanoma; Group and committee leadership updates; remembering a dear colleague and friend
November 16, 2021
The phase 3 DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma